Endocrine Society Experts Issue Clinical Practice Guideline on Hypopituitarism October 13, 2016 | Guideline calls for hormone replacement therapy to restore hormones to healthy levels. The Endocrine Society today issued a Clinical Practice Guideline that recommends treating insufficient hormone levels in individuals with hypopituitarism by replacing hormones at levels as close to the body’s natural patterns as possible. The guideline, titled “Hormonal Replacement…
Explore highlights of current education across the Endocrine Society.
Adult Growth Hormone Deficiency
CEU Satellite Session | 2.25 AMA PRA Category 1 Credits™
Chair: Mark E. Molitch, MD
Faculty: Beverly M.K. Biller, MD and Nelly Mauras, MD
Learn about testing, diagnosis, and resassessment and devise therapy and long-term managementof GH-deficient patients.
CEU Session | No credit available
Roberto R. Salvatori, MD
Follow a discussion on causes, treatment, and what patients can expect over time in cases of hypopituitarism with an emphasis on the Society’s recent practice guidelines.
Selecting a Target in Refractory Cushing Disease
ENDO Session | No credit available
Maria Fleseriu, MD
What’s your best option? Use the latest information on medical therapies from clinical trials to treat your patients with persistent disease.
Endocrine Fellows Series: Pituitary Disorders Conference 2016
Fellows Workshop Webcast | 14.0 AMA PRA Category 1 Credits™
Program Directors: Anne Klibanski, MD and Janet Schlechte, MD
Engage in a comprehensive program of current topics for pediatric and adult endocrine fellows including imaging, treatment modalities, practice management strategies, and practical approaches to challenging cases.
Endocrine Facts & Figures: Hypothalamic-Pituitary
Research Resource | No credit available
Advisory Panel Chair: Robert A. Vigersky, MD
Updated epidemiological data and in-depth discussion on pituitary dysfunction, pituitary adenomas, and other sellar lesions with current citations and expert insights.
Pseudoacromegaly: A Differential Diagnostic Problem for Acromegaly With a Genetic Solution JES | July 14, 2017 Per Dahlqvist, Rupert Spencer, Pedro Marques, Mary N Dang, Camilla A M Glad, Gudmundur Johannsson, and Márta Korbonits
Diagnosis of acromegaly is often delayed several years after onset of symptoms. However, once the disease is suspected, the diagnostic process is usually uncomplicated. Patients occasionally present with clinical aspects of acromegaly…
The Gut Metagenome Changes in Parallel to Waist Circumference, Brain Iron Deposition and Cognitive Function JCEM | June 7, 2017 Gerard Blasco, Jose Maria Moreno-Navarrete, Mireia Rivero, Vicente Perez-Brocal, Josep Garre-Olmo, Josep Puig, Pepus Daunis-i-Estadella, Carles Biarnes, Jordi Gich, Fernando Fernandez-Aranda, Angel Alberich-Bayarri, Andres Moya, Salvador Pedraza, Wifredo Ricart, Miguel Lopez, Manuel Portero-Otin, and Jose-Manuel Fernandez-Real
Microbiota perturbations seem to exert modulatory effects on emotional behavior, stress-and pain-modulation systems in adult animals; however, limited information is available in humans…
Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study JCEM | April 12, 2017 Tina Constantin, Vin Tangpricha, Reshma Shah, Nelson M. Oyesiku, Octavian C. Ioachimescu, James Ritchie, and Adriana G. Ioachimescu
Some acromegaly patients exhibit hypercalcemia or hypercalciuria. The etiology of hypercalcemia includes primary hyperparathyroidism or 1,25-dihydroxy-vitamin D [1,25(OH)2D] excess. Studies in patients …
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas JCEM | March 13, 2017 Federico Gatto, Richard A. Feelders, Sanne E. Franck, Peter M. van Koetsveld, Fadime Dogan, Johan M. Kros, Sebastian J. C. M. M. Neggers, Aart-Jan van der Lely, Steven W. J. Lamberts, Diego Ferone, and Leo J. Hofland
First-generation somatostatin analogs (SSAs), such as octreotide (OCT), are the first line medical therapy for acromegaly. Pasireotide (PAS), a newly developed SSA, has shown promising results in the treatment of acromegaly…
Disruption of the GH Receptor Gene in Adult Mice Increases Maximal Lifespan in Females Endcrinology | October 12, 2016 Riia K. Junnila, Silvana Duran-Ortiz, Ozan Suer, Elahu G. Sustarsic, Darlene E. Berryman, Edward O. List, and John J. Kopchick
GH and IGF-1 are important for a variety of physiological processes including growth, development, and aging. Mice with reduced levels of GH and IGF-1 have been shown to live longer than wild-type…
Hormonal Replacement in Hypopituitarism in Adults JCEM | October 13, 2016 Maria Fleseriu (chair), Ibrahim A. Hashim, Niki Karavitaki, Shlomo Melmed, M. Hassan Murad, Roberto Salvatori, and Mary H. Samuels
Using an evidence-based approach, this guideline addresses important clinical issues regarding the evaluation and management of hypopituitarism in adults, including appropriate biochemical assessments, specific therapeutic decisions…
Acromegaly JCEM | October 30, 2014 Laurence Katznelson, Edward R. Laws Jr, Shlomo Melmed, Mark E. Molitch, Mohammad Hassan Murad, Andrea Utz, and John A. H. Wass
Using an evidence-based approach, this acromegaly guideline addresses important clinical issues regarding the evaluation and management of acromegaly, including the appropriate biochemical assessment, a therapeutic algorithm…
Treatment of Cushing's Syndrome JCEM | July 29, 2015 Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, M. Hassan Murad, John Newell-Price, Martin O. Savage, and Antoine Tabarin
Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes…
Diagnosis and Treatment of Hyperprolactinemia JCEM | July 2, 2013 Shlomo Melmed, Felipe F. Casanueva, Andrew R. Hoffman, David L. Kleinberg, Victor M. Montori, Janet A. Schlechte, and John A. H. Wass
Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced…
Evaluation and Treatment of Adult Growth Hormone Deficiency JCEM | July 2, 2013 Mark E. Molitch, David R. Clemmons, Saul Malozowski, George R. Merriam, and Mary Lee Vance
Growth Hormone Deficiency (GHD) can persist from childhood or be newly acquired. Confirmation through stimulation testing is usually required unless there is a proven genetic/structural…
Pituitary Incidentaloma JCEM | July 2, 2013 Pamela U. Freda, Albert M. Beckers, Laurence Katznelson, Mark E. Molitch, Victor M. Montori, Kalmon D. Post, and Mary Lee Vance
We recommend that patients with a pituitary incidentaloma undergo a complete history and physical examination, laboratory evaluations screening for hormone hypersecretion and for hypopituitarism, and…
The Diagnosis of Cushing's Syndrome JCEM | January 14, 2009 Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, John Newell-Price, Martin O. Savage, Paul M. Stewart, and Victor M. Montori
After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with…
For additional meetings, visit the Endocrine Society’s Worldwide Endocrinology Calendar at endocrine.org/calendar.
Clinical Endocrinology Update & Endocrine Board Review Dates: September 23–27, 2017 Location: Chicago, Illinois, United States Sponsor: Endocrine Society
Whether you need the latest clinical information or you’re preparing to certify or recertify for the boards, Clinical Endocrinology Update (CEU) and Endocrine Board Review (EBR) have you covered.
ENDO 2018 Dates: March 17–20, 2018 Location: Chicago, Illinois, United States Sponsor: Endocrine Society
ENDO is the world’s largest event for presenting and obtaining the latest in endocrine science and medicine with an extensive program covering a broad array of topics, various networking opportunities, poster sessions, updates on new products and technologies at the ENDOExpo, and more.